Category: Treatment


Making the Most Out of Immunotherapy

11 June 2018 In Science, Treatment

Learn what MRA-funded investigators are doing to optimize immunotherapy for patients.

Read More


We’ve Teamed Up with the American Cancer Society

By Cody R. Barnett, MRA Director of Communications | 7 June 2018 In Allies & Partnerships, Science, Treatment

American Cancer Society and Melanoma Research Alliance have united to fund lifesaving research aimed at reducing side effects and improving outcomes for patients treated with immunotherapy.

Read More


Tackling Brain Metastases

30 April 2018 In Science, Treatment

Brain metastases (mets) are a frequent and often deadly problem in patients with advanced melanoma. Nearly 40% of patients with metastatic melanoma have brain mets at diagnosis, with an average survival of only 4 months, suggesting a crucial need for treatments that can rid the brain of these tumors1,2. But new cancer treatments are rarely tested in patients with active brain mets. This is largely due to concerns about whether these patients will have side effects unique to brain mets, and poorer outcomes that may negatively weigh against otherwise positive clinical benefits. Another potential concern is whether the drugs will even penetrate the brain, which has a fortress-like ability to keep substances from entering it.

Read More


Immunotherapy & Chemotherapy – Two Different Approaches

By Cody R. Barnett, MRA Director of Communications | 21 March 2018 In Science, Treatment

We’ve all seen the movie where the heroic cancer patient bravely moves through treatment as she deals with nausea, hair loss, and other side effects. For many cancer patients this picture is true, however imprecise. Hollywood has conditioned us to equate cancer treatment with chemotherapy. Twenty years ago this narrative was more or less accurate, but in a world where immunotherapies and other new treatments are increasingly being used, this narrative isn’t keeping up with today’s reality. For some people with melanoma, this stuck-in-the-past narrative may even be deadly.

Read More


What’s Next in Melanoma Treatment?

By Cody R. Barnett, MRA Director of Communications | 20 March 2018 In Science, Treatment

Dr. Douglas Johnson, MRA Young Investigator awardee and Assistant Professor of Medicine and Melanoma Clinical Director at the Vanderbilt-Ingram Cancer Center, outlines three broad areas of current and future melanoma research.

Read More


Finding the Magic Formula

By Cody R. Barnett, MRA Director of Communications | 7 February 2018 In Science, Treatment

Modern immunotherapy, with melanoma as its poster child, is changing the way we treat cancer - for good. But, so far at least, it isn't helping everyone. Many scientists believe that there isn't a single silver bullet to unleash the awesome power of our immune systems - and instead - that the future of oncology is finding just the right combination of therapies that push and pull from different directions to multiply and enhance each other's effectiveness.

Read More


The Hidden Costs of Cancer

By Cody R. Barnett, MRA Director of Communications | 12 January 2018 In Melanoma Stories, Treatment

The National Cancer Institute estimates that between 33 and 80% of cancer survivors exhaust their savings to finance their medical expenses. Up to three percent of survivors file for bankruptcy, 260 times more frequently than similar households not affected by cancer. Not only is this financially devastating for families, this hardship was the strongest predictor of the quality of life for cancer survivors.

Read More


FDA Approves Nivolumab in Adjuvant Setting - Is it a Big Deal?

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 21 December 2017 In News, Science, Treatment

The US FDA approved the use of nivolumab (Opdivo) in the adjuvant setting on December 20, 2017. This means that nivolumab may be used to treat melanoma patients with lymph node involvement or metastatic disease after complete surgical resection to reduce the risk of their disease recurring.

Read More


Introducing Clinical Trial Navigator: Start Searching Today

By Cody R. Barnett, MRA Director of Communications | 5 December 2017 In Allies & Partnerships, News, Science, Treatment

At MRA, we know that advancing science is our best bet in the fight against melanoma. More than 87,000 people in the US will be diagnosed with melanoma this year, and with these numbers on the rise, researchers are working harder than ever to find new and better treatment options. In fact, there are over 300 clinical trials happening in melanoma right now.

Read More


Spotlight on Immunotherapy: Genetic Makeup of Tumors Informs use of anti-PD-1 drugs for Multiple Cancer Types

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 6 October 2017 In News, Science, Treatment

Imagine the powerlessness one must feel after undergoing rigorous treatment for cancer only to find that your tumor is non-responsive. However – new hope may be on the horizon. In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Pembrolizumab for treatmentof patients whose cancers possess a genetic mutation in the mismatch repair pathway (mismatch repair deficient, or dMMR) or are microsatellite instability-high (MSI-H). This is the first time the agency approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

Read More


Login

×